T1	intervention 14 25	Palbociclib
T2	control 780 795	letrozole alone
T5	intervention-participants 879 881	66
T6	control-participants 934 936	99
T7	outcome-Measure 1027 1058	progression-free survival (PFS)
T8	outcome 1096 1099	PFS
T11	total-participants 621 624	165
T12	eligibility 366 461	postmenopausal women with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer
T3	outcome 1311 1327	clinical benefit
